The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

- Recognized for its industry leading opti-ox™ technology that produces cultivated meat with speed and efficiency, Meatable leads industry on quest to solve protein shortages and food insecurity ...

bit.bio is a synthetic biology company that uses its cell identity coding platform to reprogram induced pluripotent stem cells to create any human cell type. With its cell identity coding platform, ...

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

Research collaboration leverages bit.bio's machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into ...

BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.